Ginkgo Bioworks will become a multi-year microbial strategic partner with Bayer in their work to develop biological solutions in fields like nitrogen optimisation, carbon sequestration, and next generation crop protection
Bayer recently announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer’s West Sacramento Biologics Research & Development (R&D) site and internal discovery and lead optimisation platform. The contemplated transaction, projected to close before the end of 2022 pending final negotiation of the agreement terms and subject to regulatory approvals, would also bring Joyn Bio’s nitrogen-fixing technologies to Bayer, successfully closing the joint venture created between Leaps by Bayer and Ginkgo Bioworks in 2017.
Ginkgo Bioworks will become a multi-year microbial strategic partner with Bayer in their work to develop biological solutions in fields like nitrogen optimisation, carbon sequestration, and next generation crop protection.
The transaction will enable Bayer to expand its leading biologicals position, strengthen its access to key enabling technology in synthetic biology, and maintain Bayer’s role as the preferred research, development, and commercial partner in the biologics segment.
“Bayer’s work in the rapidly growing biologics space is an essential part of our commitment to sustainability and providing effective climate-smart products like nitrogen fixing and optimization technologies,” said Bob Reiter, Head of R&D for Bayer’s Crop Science Division. “Our work with Ginkgo will accelerate our biologicals pipeline by leveraging Bayer’s expertise in bringing reliable and effective biological products to market against Ginkgo’s synthetic biology research engine – now enhanced by an expanded ag biologics research and development platform – and help Bayer continue to expand our biologics product range to create tailored solutions for additional crops.”
This strategic shift to an exclusively external biologics research discovery pipeline with leading partners will activate the international open innovation ecosystem and equip Bayer to better leverage its proven capability in commercialising biologicals to create category-leading products that meet the growing need for climate-smart and sustainable options that complement traditional chemistries.
